Clinical Trial Update: A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ASP1893 in adults with CLDN6-positive solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Solid Tumor
• Testicular Cancer

Drugs mentioned

• ASP1893

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: CLDN6-positive Solid Tumor, Ovarian Cancer | Phase 1 | Status: WITHDRAWN